Cytokinetics (Nasdaq: CYTK) announced inducement equity awards granted April 15, 2026 to 33 new employees hired March–April 2026.
The company granted 49,358 stock options (10-year term, $65.37 exercise price) and 32,734 RSUs that vest over three years per the stated schedule. Awards follow Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CYTK
-0.51%
-0.51%Session close to close
In the Apr 21 session, CYTK declined 0.51%, reflecting a mild negative market reaction.
This announcement details equity inducement grants—stock options and 32,734 RSUs—issued to 33 recent...
Analysis
This announcement details equity inducement grants—stock options and 32,734 RSUs—issued to 33 recent hires under Nasdaq Listing Rule 5635(c)(4). The options carry a $65.37 exercise price and a 10-year term, with multi-year vesting schedules designed to retain talent. In recent months, the company has paired such routine equity and conference updates with more material events like its Feb 24, 2026 earnings release and MYQORZO approvals. Investors may watch future financial reports and clinical milestones for more directional catalysts than these compensation-related filings.
Key Figures
Stock options granted:49,358 sharesRSUs granted:32,734 RSUsEmployees receiving awards:33 employees+5 more
8 metrics
Stock options granted49,358 sharesInducement options granted on April 15, 2026
RSUs granted32,734 RSUsInducement RSUs granted to new employees
Employees receiving awards33 employeesNew hires in March and April 2026
RSU vesting term3 yearsInducement RSUs vest over three years
RSU vesting schedule40% / 40% / 20%Annual vesting on years 1, 2, and 3
Option exercise price$65.37 per shareEqual to CYTK closing price on April 15, 2026
Option vesting term4 yearsQuarterly then monthly vesting subject to service
Option term10 yearsContractual life of inducement stock options
Q4 and 2025 results with MYQORZO approvals, $88M revenue, and 2026 spend guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Smaller corporate and conference updates have seen modest positive moves, while the latest earnings/business update on Feb 24 coincided with a sharper -10.29% decline.
Recent Company History
Over the past six months, Cytokinetics has mainly issued conference participation updates, scientific presentation news, inducement grant announcements, and a key earnings report. The Feb 24, 2026 earnings and business update, which highlighted MYQORZO approvals and cash of $1.22 billion, saw a notable -10.29% reaction. Subsequent news—including ACC 2026 presentations, investor conference appearances, and prior inducement grants—generated modest price changes within a few percent, suggesting routine corporate communications have had limited directional impact compared with larger financial updates.
Key Terms
stock options, restricted stock units, RSUs, exercise price, +2 more
6 terms
stock optionsfinancial
"it granted stock options to purchase an aggregate of 49,358 shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
restricted stock unitsfinancial
"and 32,734 restricted stock units (RSUs) that will be settled in shares of common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUsfinancial
"32,734 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
exercise pricefinancial
"The stock options that were granted are subject to an exercise price of $65.37 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
equity incentive planfinancial
"terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Nasdaq Listing Rule 5635(c)(4)regulatory
"material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49,358 shares of common stock and 32,734 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 33 employees, whose employment commenced in March and April 2026 as a material inducement to their employment.
The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $65.37 per share, which is equal to the closing price of the Company’s common stock on April 15, 2026 and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.
The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
Disclaimer Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.
How many shares did Cytokinetics (CYTK) grant as inducement awards on April 15, 2026?
Cytokinetics granted a total of 82,092 equity awards as inducements on April 15, 2026. According to the company, that total comprises 49,358 stock options and 32,734 RSUs issued to 33 new employees.
What is the vesting schedule for the RSUs granted by Cytokinetics (CYTK)?
The RSUs vest over three years with 40% at year one, 40% at year two, and 20% at year three. According to the company, vesting is subject to each employee's continued service.
What are the terms of the stock options Cytokinetics (CYTK) granted April 15, 2026?
Stock options have a 10-year term and an exercise price of $65.37, equal to the April 15, 2026 close. According to the company, options vest over four years with 1/4 after one year, then monthly thereafter.
Do Cytokinetics' (CYTK) inducement awards comply with Nasdaq rules?
Yes. The awards were granted as material inducements under Nasdaq Listing Rule 5635(c)(4). According to the company, the grants were made in accordance with that Nasdaq provision.
How many employees received inducement grants from Cytokinetics (CYTK) in April 2026?
A total of 33 employees received inducement grants in March–April 2026. According to the company, the awards were granted to employees whose employment commenced in March and April 2026.
What is the exercise price significance for CYTK stock options granted April 15, 2026?
The exercise price of $65.37 equals the company's closing stock price on April 15, 2026. According to the company, setting exercise price at closing price aligns option strike with that trading-day value.
